'Parp inhibitor' diaporamas de présentation

The Role of PARP inhibitors in Breast Cancer

The Role of PARP inhibitors in Breast Cancer. QROC November 5 th , 2010 Rebecca Dent, MD FRCP(C) Sunnybrook Odette Cancer Center Toronto, Canada. Potential Conflict of Interest. Dr. Rebecca Dent AstraZeneca, consultant and honorariat (2007-2010)

960 views • 49 slides

PARP Inhibitors: Usurping DNA repair to target cancer

PARP Inhibitors: Usurping DNA repair to target cancer. Lee Schwartzberg MD, FACP Chief Medical Officer The West Clinic. Question 1. DNA repair mechanisms are important in Cancer cells only Both cancer and normal eukaryotic cells

2.21k views • 39 slides

PARP Inhibitors: Usurping DNA repair to target cancer

PARP Inhibitors: Usurping DNA repair to target cancer. Lee Schwartzberg MD, FACP Chief Medical Officer The West Clinic. Question 1. DNA repair mechanisms are important in Cancer cells only Both cancer and normal eukaryotic cells

779 views • 39 slides

Pharmacodynamic Paradigms in Early-Phase Cancer Clinical Trials

Pharmacodynamic Paradigms in Early-Phase Cancer Clinical Trials. Workshop Phase 0 Trials In Oncologic Drug Development. Hilary Calvert Northern Institute for Cancer Research. Methodology for Phase I and Phase 0 (translational) Trials.

1.03k views • 34 slides

364 views • 27 slides

Co-Principal Investigators: Sandra Strauss, MD, PhD University College London Rashmi Chugh , MD

ESP1/SARC025. ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP inhibitor, Niraparib and Temozolomide in Patients with Previously Treated, incurable Ewing Sarcoma. Co-Principal Investigators: Sandra Strauss, MD, PhD University College London

203 views • 10 slides